|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1300 Wilson Boulevard |
Address2 | Suite 600 |
City | Arlington |
State | VA |
Zip Code | 22209 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Arlington |
State | VA |
Zip Code | 22209 |
Country | USA |
|
5. Senate ID# 401104947-12
|
||||||||
|
6. House ID# 441480001
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Abram Bieliauskas |
Date | 11/16/2020 12:44:33 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance.
The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (S. 2741/ H.R. 4932) would expand access to telemedicine and telehealth for people with ALS through a legal and regulatory environment where providers are permitted to deliver safe, high quality care using telehealth and telemedicine regardless of care delivery location or technological method. Additionally, all changes made to expand access to telehealth during the COVID-19 public health emergency should be permanently extended.
Promising Pathway Act (H.R. 7269/ S. 3872) to establish a new time-limited provisional approval path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved.
Accelerating Critical Therapies for ALS Act (H.R. 7071) reintroduced as H.R. 8662/ S. 4867 to create 1) a new framework for delivering experimental therapies to people with ALS; 2) a new research grant program at the FDA for rare neurodegenerative diseases, and; 3) a new Collaborative for Rare Neurodegenerative Diseases at the Department of Health and Human Services (HHS) to coordinate federal efforts on developing and approving effective treatments and cures.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Abram |
Bieliauskas |
|
|
|
Kathleen |
Sheehan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Requested that House and Senate Defense Appropriations Subcommittee provide $40 million for the ALS Research Program at the Department of Defense, a $20 million increase over the ALSRP's funding in FY2020. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum.
Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention.
Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $44.7 billion for the NIH, a $3 billion increase over NIHs program level funding in FY 2020. This funding level would allow for meaningful growth above inflation in the base budget and would expand NIHs capacity to support promising science in all disciplines across the agency. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Abram |
Bieliauskas |
|
|
|
Kathleen |
Sheehan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Requested Congress fix the law to allow Medicare beneficiaries with ALS to receive home infusion of IV medications. As the disease progresses, people with ALS face increased mobility challenges, eventually becoming homebound and requiring care at home. Under current law, there is no Medicare coverage of home infusion for ALS drugs. Medicare Part B beneficiaries must leave the home to receive infusions at a hospital, doctors office or infusion center; Medicare Part D only covers the IV medication, leaving beneficiaries to pay out-of-pocket for home infusion pharmacy and nursing services. Private insurance fully covers home infusion. The ALS Association is advocating to expand Medicare coverage of home infusion that is equivalent to private coverage.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Abram |
Bieliauskas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
The Justice for ALS Veterans Act (S. 3091/H.R. 4748) would increase dependency and indemnity compensation (DIC) paid to surviving spouses of veterans who die from ALS regardless of how long the veteran had ALS prior to death. Because ALS is a service-connected disease, families of deceased veterans receive a DIC. However, they are denied a supplemental DIC increase available only to families of veterans who live at least eight years with a service-connected disability. Families of veterans who died from ALS deserve the same compensation as other military families.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Abram |
Bieliauskas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |